Patents Examined by Karen E. Brown
  • Patent number: 5629162
    Abstract: The present invention relates to intercellular adhesion molecules (ICAM-3) which is involved in the process through which lymphocytes recognize and migrate to sites of inflammation as well as attach to cellular substrates during inflammation. The invention is directed toward such molecules, screening assays for identifying such molecules and antibodies capable of binding such molecules. The invention also includes therapeutic and diagnostic uses for adhesion molecules and for the antibodies that are capable of binding them.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: May 13, 1997
    Assignee: The Center for Blood Research
    Inventors: Antonin R. deFougerolles, Timothy A. Springer
  • Patent number: 5622930
    Abstract: Compositions consisting of C1 inhibitor muteins having biological activity similar to C1 inhibitor, but with enhanced resistance to proteolytic cleavage thus rendering such muteins suitable as anti inflammatory agents, preferably for the treatment or prevention of sepsis.
    Type: Grant
    Filed: September 5, 1991
    Date of Patent: April 22, 1997
    Assignee: CLB
    Inventors: Eric Eldering, Lucien Aarden
  • Patent number: 5621078
    Abstract: Pseudomonas exotoxin 40 is modified by deleting or substituting one or more cysteine residues. Such a modified protein, when hybridized to TGF.alpha., exhibits altered biological activities from unmodified TGF.alpha. PE.sub.40, including decreased cell killing activity and increased receptor-binding activity.
    Type: Grant
    Filed: February 21, 1995
    Date of Patent: April 15, 1997
    Assignee: Merck & Co., Inc.
    Inventors: Mark W. Riemen, Steven M. Stirdivant
  • Patent number: 5612312
    Abstract: A method of chronic modification of cell barrier properties by exposing a cell to a modification-effective amount of IGF-I for at least about 7 days wherein the modification effective amount is between about 50 .mu.g/kg and less than about 500 .mu.g/kg is disclosed. Further disclosed is a method of chronic amelioration or reversal of insulin resistance as well as a method of diagnosing and screening for rhIGF-I sensitive cell barrier properties.
    Type: Grant
    Filed: May 8, 1995
    Date of Patent: March 18, 1997
    Inventors: Alan C. Moses, Linda A. Morrow, Jeffrey S. Flier
  • Patent number: 5599792
    Abstract: Described herein are Met.sup.8 -substituted variants of parathyroid hormone that retain bone stimulating activity yet, unlike their native counterparts, have substantially no vasoactivity. Their production using recombinant DNA-based techniques is also described, as is their therapeutic use, e.g. in the treatment of osteoporosis.
    Type: Grant
    Filed: October 31, 1994
    Date of Patent: February 4, 1997
    Assignee: Allelix Biopharmaceuticals Inc.
    Inventors: K. Anne Kronis, Richard P. Bozzato
  • Patent number: 5587462
    Abstract: Isolated, substantially pure mammalian brain-derived membrane-associated CRF-binding proteins and biologically active fragments thereof are provided as well as isolated and purified DNA fragments which encode the CRF binding proteins or biologically active fragments thereof or homologs of other mammalian species. By administering an amount of such CRF binding protein or a fragment thereof effective to modulate receptor activation, it is possible to modulate the action of CRF upon (a) the brain and nervous system, (b) the pituitary particularly for production of ACTH, beta endorphin and cortisol, (c) sites of inflammation, (d) the placenta, (e) the adrenal glands, (f) the gonads or (g) the gastrointestinal tract. Administration of an N-terminal fragment of the protein increases the binding site density for CRF and thus modulates its biological effect in vivo.
    Type: Grant
    Filed: November 8, 1993
    Date of Patent: December 24, 1996
    Assignee: The Salk Institute For Biological Studies
    Inventors: Dominic P. Behan, Wylie W. Vale, Jr., Wolfgang H. Fischer, Philip J. Lowry
  • Patent number: 5585463
    Abstract: .beta..sub.3 integrin subunit specific polypeptides, cDNAs which encode these polypeptides and methods of producing these polypeptides are provided.
    Type: Grant
    Filed: November 10, 1994
    Date of Patent: December 17, 1996
    Assignee: Trustees of the University of Pennsylvania
    Inventors: Sanford Shattil, Timothy O'Toole, Mark Ginsberg
  • Patent number: 5523209
    Abstract: The invention features a method for inhibiting the ligand binding of an integrin in a cell involving introducing into the cell a compound which inhibits integrin activation, a method for identifying compounds which inhibit integrin activation, and chimeric integrin molecules.
    Type: Grant
    Filed: March 14, 1994
    Date of Patent: June 4, 1996
    Assignee: The Scripps Research Institute
    Inventors: Mark H. Ginsberg, Timothy E. O'Toole
  • Patent number: 5514652
    Abstract: The present invention relates to a preparation for the therapy of respiratory tract diseases which contains a basic fibroblast growth factor and/or a homologue thereof as an active ingredient, a preparation for the therapy of respiratory tract diseases which contains a human basic fibroblast growth factor and/or a homologue thereof, produced by microorganisms or cultured cells prepared by genetic recombination, as an active ingredient, and a method for the therapy of respiratory tract diseases by administering any one of these preparations.
    Type: Grant
    Filed: October 22, 1993
    Date of Patent: May 7, 1996
    Assignee: Kaken Pharmaceutical Co., Ltd.
    Inventors: Mitsuru Watanuki, Tsutomu Nakamura, Masaru Ogawa